DE69804463D1 - Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie - Google Patents

Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie

Info

Publication number
DE69804463D1
DE69804463D1 DE69804463T DE69804463T DE69804463D1 DE 69804463 D1 DE69804463 D1 DE 69804463D1 DE 69804463 T DE69804463 T DE 69804463T DE 69804463 T DE69804463 T DE 69804463T DE 69804463 D1 DE69804463 D1 DE 69804463D1
Authority
DE
Germany
Prior art keywords
cationic polymers
gene therapy
negative charge
therapeutically active
nucleic acids
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69804463T
Other languages
English (en)
Other versions
DE69804463T2 (de
Inventor
V Kolbe
Otmane Boussif
Thierry Delair
Laurent Veron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transgene SA
Original Assignee
Transgene SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9709209A external-priority patent/FR2766194A1/fr
Application filed by Transgene SA filed Critical Transgene SA
Application granted granted Critical
Publication of DE69804463D1 publication Critical patent/DE69804463D1/de
Publication of DE69804463T2 publication Critical patent/DE69804463T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F126/00—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen
    • C08F126/02—Homopolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen by a single or double bond to nitrogen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
DE69804463T 1997-07-21 1998-07-20 Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie Expired - Fee Related DE69804463T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9709209A FR2766194A1 (fr) 1997-07-21 1997-07-21 Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique
FR9715807A FR2766195A1 (fr) 1997-07-21 1997-12-12 Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charges negative, notamment des acides nucleiques, et leur utilisation en therapie genique
PCT/FR1998/001581 WO1999005183A1 (fr) 1997-07-21 1998-07-20 Polymeres cationiques, complexes associant lesdits polymeres cationiques et des substances therapeutiquement actives comprenant au moins une charge negative, notamment des acides nucleiques, et leur utilisation en therapie genique

Publications (2)

Publication Number Publication Date
DE69804463D1 true DE69804463D1 (de) 2002-05-02
DE69804463T2 DE69804463T2 (de) 2002-10-10

Family

ID=26233691

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69804463T Expired - Fee Related DE69804463T2 (de) 1997-07-21 1998-07-20 Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie

Country Status (12)

Country Link
US (1) US6407178B1 (de)
EP (1) EP0998501B1 (de)
JP (1) JP2001510863A (de)
AT (1) ATE215099T1 (de)
AU (1) AU740392B2 (de)
CA (1) CA2297487A1 (de)
DE (1) DE69804463T2 (de)
DK (1) DK0998501T3 (de)
ES (1) ES2172180T3 (de)
FR (1) FR2766195A1 (de)
PT (1) PT998501E (de)
WO (1) WO1999005183A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030134420A1 (en) * 2000-02-18 2003-07-17 Lollo Charles Peter Methods and compositions for gene delivery
WO2002032396A2 (en) * 2000-10-16 2002-04-25 Massachusetts Institute Of Technology Lipid-protein-sugar particles for delivery of nucleic acids
CN1511039A (zh) * 2001-04-18 2004-07-07 ԭ���ø� 降低血浆葡萄糖的方法
AU2003243360A1 (en) * 2002-05-31 2003-12-19 Genteric, Inc. Polyamine-mediated transfection
WO2003102150A2 (en) * 2002-05-31 2003-12-11 Genteric, Inc. Multi-functional polyamines for delivery of biologically-active polynucleotides
DE10310196A1 (de) * 2003-03-06 2004-09-23 Rina-Netzwerk Rna Technologien Gmbh Verwendung eines trizyklischen Antidepressivums zur Förderung der Endozytose
CA2536120A1 (en) * 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
ES2411962T3 (es) 2003-10-24 2013-07-09 Gencia Corporation Métodos y composiciones para suministrar polinucleótidos
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
US20070176158A1 (en) * 2006-02-01 2007-08-02 Robinson Jeffery A Portable safety barrier
US8686129B2 (en) * 2007-03-20 2014-04-01 Agilent Technologies, Inc. Methods for the separation of biological molecules using sulfolane
US8357531B2 (en) 2007-07-03 2013-01-22 Transgene S.A. Immortalized avian cell lines
JP2010539245A (ja) * 2007-09-14 2010-12-16 日東電工株式会社 薬物担体
AU2015270888B2 (en) * 2008-05-28 2017-11-16 Wayne State University Method and composition for a protein transduction technology and its applications
US8722348B2 (en) * 2008-05-28 2014-05-13 Wayne State University Method and composition for a protein transduction technology and its applications
DK3060237T3 (da) 2013-10-25 2021-10-25 Univ Wayne State Modificeret omprogrammeringsprotein til anvendelse i behandling af cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3325472A (en) * 1964-06-18 1967-06-13 Mortimer D Sackler Polycyclohexose-polyoxyethyleneglycol suppository bases
US3440320A (en) * 1964-06-18 1969-04-22 Mortimer D Sackler Chelated suppository and method of using same
JPS60106804A (ja) * 1983-11-15 1985-06-12 Nitto Boseki Co Ltd ポリアリルアミンから誘導される新規な機能性樹脂
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
SE467309B (sv) * 1990-10-22 1992-06-29 Berol Nobel Ab Hydrofiliserad fast yta, foerfarande foer dess framstaellning samt medel daerfoer
ES2096150T3 (es) * 1992-07-22 1997-03-01 Hoechst Ag Copolimeros vinilicos reticulados, procedimiento para su preparacion, asi como el empleo de estos compuestos.
ATE159262T1 (de) * 1992-07-22 1997-11-15 Hoechst Ag Hydrophile zentren aufweisende polyvinylamin- derivate, verfahren zu ihrer herstellung sowie die verwendung der verbindungen als arzneimittel, wirkstoffträger und nahrungsmittelhilfsstoff
DE4227019A1 (de) * 1992-08-14 1994-02-17 Geckeler Kurt E Priv Doz Dr Herstellung und Modifikation von Materialien auf der Basis von Amino- oder Amidpolymeren
DE4322884A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Biologisch aktive Polymere
US5260385A (en) * 1992-11-02 1993-11-09 Director-General Of Agency Of Industrial Science And Technology Biguanide group-containing polyallylamine and method of producing same
JPH09504308A (ja) * 1993-07-23 1997-04-28 マサチューセッツ インスティチュート オブ テクノロジー 非直鎖状の親水性−疎水性マルチブロックコポリマーのナノ粒子およびマイクロ粒子
US5629184A (en) * 1995-01-25 1997-05-13 Amgen Inc. Cationic copolymers of vinylamine and vinyl alcohol for the delivery of oligonucleotides

Also Published As

Publication number Publication date
PT998501E (pt) 2002-08-30
DE69804463T2 (de) 2002-10-10
CA2297487A1 (fr) 1999-02-04
AU8813198A (en) 1999-02-16
ES2172180T3 (es) 2002-09-16
JP2001510863A (ja) 2001-08-07
DK0998501T3 (da) 2002-07-01
US20020031763A1 (en) 2002-03-14
ATE215099T1 (de) 2002-04-15
EP0998501A1 (de) 2000-05-10
AU740392B2 (en) 2001-11-01
US6407178B1 (en) 2002-06-18
FR2766195A1 (fr) 1999-01-22
WO1999005183A1 (fr) 1999-02-04
EP0998501B1 (de) 2002-03-27

Similar Documents

Publication Publication Date Title
DE69804463D1 (de) Kationische polymere, diese kationische polymere enthaltende komplexe und wenigstens eine negative ladung enthaltende therapeutisch wirksame mittel, insbesondere nukleinsäuren und ihre verwendung in gentherapie
ATE334664T1 (de) Zelldurchlässige peptide zur inhibierung von entzündungsreaktionen und deren verwendung
DE69943068D1 (de) Transfer von mRNA unter Verwendung von polykationischen Verbindungen
BR9914643A (pt) Vetores adeno-associados para expressão dofator viii por células alvo
DE50006269D1 (de) Kombinationen zur einführung von nucleinsäuren in zellen
KR950702626A (ko) 치료제로서 자체-안정화된 올리고누클레오티드(self-stabilized loigonucleotides as therapeutic agents)
DE3650753D1 (de) Auf einmaligen sequenzen innerhalb des veränderlichen gebiets des t-zellrezeptors basierte diagnosemittel und deren verwendung
CA2045891A1 (en) Oligonucleotide analogs with terminal 3'-3' or 5'-5' internucleotide linkages
DE69535540D1 (de) Zusammensetzung enthaltend nukleinsäuren und kationische polymere, zubereitung und verwendung
DE69535576D1 (de) Zusammensetzungen von nucleinsäure und viskosität-erhöhendem polymer pvp, zur verwendung in gentherapie
DE69534669D1 (de) Nukleinsaeure enthaltende zusammensetzungen, herstellung und verwendung
ES2115096T3 (es) Derivados tetrazolicos de acidos biliares, procedimiento para su preparacion y utilizacion de estos compuestos como medicamentos.
TR200400149T2 (tr) Tümörlerin teşhisi ve tedavisi için mikroorganizmalar ve hücreler
BR0109062A (pt) Inibidores de frutose-1,6-bisfosfatase de arila
DE69828045D1 (de) Verbindungen, ihre herstellung und ihre verwendung für den transfer von nucleinsäuren in zellen
TR199802648A2 (xx) Gen tedavisi i�in n�klein asit yap�lar�.
CA2155017A1 (en) Vpr function and activity
NZ504445A (en) Nucleic acid sequences of genes of the high mobility group proteins and their use in treating tumours, vascular disorders and as a contraceptive
NZ500300A (en) Compositions containing N-(3,4-dimethoxycinnamoyl) anthranilic acid for the treatment of excessive proliferation of retinal pigment epithelial cells
SE9503117D0 (sv) Novel use of padlock probes
DE69934415D1 (de) Neuartiges collectin
ES2144992T3 (es) Oligonucleotidos, marcados y modificados.
BR9909044A (pt) Vetor de tranferência de ácidos nucleicos, composição, utilização de um vetor de tranferência de ácidos nucleicos, processos de transfecção de ácidos nucleicos nas células, e de tratamento de doenças, e, célula recombinante
ATE249243T1 (de) Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat
ES2157617T3 (es) Nuevos derivados de benzoxacindionas conjugados con principios activos.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee